CellLine	PAM50	SCMOD2	SCMGENE	AIMS	intClust	Lehmann	Type	BRCA	Screenable	RNAseq (availability) link available from Benjamin	SNP (availability) 	ATACseq 2018 (availability with the Lupien lab)	ATACseq 2022	Location on Mordor :(/mnt/work1/users/lupiengroup/People/nergiz/ATAC/fastq_TNBCcells/)	ATACseq 2021 (PE)	STR status (EV) assessed on the stocks kept by the Lupien lab (legend: 0 = unmatched, 1 = perfect match)	Mycoplasma testing	Mutations called (exome-seq available) Link available from Benjamin	GARP score _COLT screen)	CRISPR/Cas9 stable	CRISPR/dCas9-KRAB stable	INCUCYTE Epigenetic probe screen (Arrowsmith/Lupien)	Dose-Dependent Response Epigenetic probe screen (Dave)	Vials position LupienLab stocks	notes	Colour code	ATAC-processing-stage	Currently-growing-DC-lab	 
184A1	Normal	Basal	Basal	Her2	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2	normal			Y								N							chemically transformed	o			
184B5	Normal	Basal	LumA	Her2	iC3 [luminal A]	BL2	normal			Y								N							chemically transformed	o			
600MPE	LumB	LumB	LumB	Her2	iC8 [Lumninal A, 1q gain/16q loss]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				N								g			
AU565	Her2	HER2	HER2	Her2	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	LAR	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				Y								g	LC	growing	
BT-20	Basal	Basal	LumB	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2	primary		Y	Y		Y	Y	BT20_1_S8_L003_R1_001.fastq.gz, BT20_7_S14_L004_R1_001.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/220609_A00827_0591_AHY7F3DRXY_Lupien_Giacomo			Neg	Y	Y					Stack 3 Rack 9 (6 vials)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	y	LC	Jennifer growing	
BT-474	LumB	HER2	HER2	Her2	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	Possible ER+	primary		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				Y						Stack 3 Rack 9 (2 vials)		o	LT	growing	
BT-483	LumB	LumB	LumB	LumB	iC8 [Lumninal A, 1q gain/16q loss]	Possible ER+	primary			Y								Y								g			
BT-549	Basal	Basal	Basal	Basal	iC10 [basal-like, cis-acting alterations (5 loss/8q gain/10p gain/12p gain)]	M	primary		Y	Y		Y	Y	BT549_3_CAGAGA_L002_R1.fastq.gz, BT549_6_GCTACG_L003_R1.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina		1	Neg	Y	Y			Y	Y	Stack 3 Rack 9 (2 vials)		g		Jennifer growing	Color Codes
CAL-120	Basal	Basal	LumB	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	M/MSL	metastatic		Y	Y		Y		CAL120_2_S11_L003_R1_001.fastq.gz, CAL120_7_S12_L003_R1_001.fastq.gz			Neg	Y				Y	Y			y			Very Good (3 classifiers have agreement [PAM50, SCMOD2, SCMGENE])
CAL-148	Her2	LumB	Basal	Her2	iC8 [Lumninal A, 1q gain/16q loss]	LAR	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				Y								o			
CAL-51	LumB	Basal	LumB	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	M	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				Y	Y							o	LC	CAL-51: growing	
CAL-85-1	Basal	Basal	LumB	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2/IM	primary			Y		Y		CAL85-1_1_S16_L004_R1_001.fastq.gz,  CAL85-1_7_S13_L004_R1_001.fastq.gz				Y								y			
CAMA-1	LumB	LumB	LumB	Her2	iC6 [ER-positive, 8p12 cis-acting luminal subgroup]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/220609_A00827_0591_AHY7F3DRXY_Lupien_Giacomo				Y								g	FRESH **[SM]/LC	growing	
DU-4475	Her2	Basal	Basal	Her2	iC3 [luminal A]	BL1/IM	metastatic			Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				Y						Stack 3 Rack 9 (2 vials)		o			
EFM-19	LumB	LumB	LumB	LumB	iC3 [luminal A]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/220928_A00827_0655_BH7HJKDRX2_Lupien_Lucie				Y						Stack 3 Rack 9 (3 vials)		g			
EFM-192A	LumA	HER2	HER2	Her2	iC3 [luminal A]	LAR	metastatic			Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				Y								o			
EVSA-T	Her2	Basal	Basal	Her2	iC7 [Lumninal A, lacks 1q alteration/16p gain/16q loss/ 8q amplification]	LAR	metastatic		Y	Y								Y								o			
HBL-100	Basal	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2/MSL	Undefined cell line type		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				N							problematic, Y chromosome, ATCC: Discontinued http://web.expasy.org/cellosaurus/CVCL_4362 	r			Good (2 classifiers have agreement [PAM50 and SCMOD2])
HCC1008	Her2	LumB	LumB	Her2	iC7 [Lumninal A, lacks 1q alteration/16p gain/16q loss/ 8q amplification]	LAR	metastatic			Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/220928_A00827_0655_BH7HJKDRX2_Lupien_Lucie				N								o			
HCC1143	Basal	Basal	LumB	Basal	iC9 [ER-positive, 8q cis-acting/20q-amplified mixed subgroup]	BL1	primary		Y	Y		Y	Y	HCC1143_4_AGGCAGAA_L003_R1.fastq.gz, HCC1143_9_AGGCAGAA_L004_R1.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina		0.91	Neg	Y	Y				Y	Stack 3 Rack 9 (1 vial)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	y	LC		Not so good but not necessarily bad (needs attention as PAM50 and SCMOD2 disagree)
HCC1187	Basal	Basal	Basal	Basal	iC10 [basal-like, cis-acting alterations (5 loss/8q gain/10p gain/12p gain)]	BL1/IM	primary		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/220609_A00827_0591_AHY7F3DRXY_Lupien_Giacomo		*Purchased from ATCC		Y						Stack 4 Rack 8 (7vials)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™) *** mix of adherent and susp. cells (difficult to perform incucyte assays on)	g		growing Jenn 	Problematic
HCC1395	Basal	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	M	primary		Y	Y		Y	Y	HCC1395_3_S4_L001_R1_001.fastq.gz, HCC1395_5_S7_L003_R1_001.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221201_A00827_0713_BHLJV3DRX2_Lupien_Lucie_Tina		*Purchased from ATCC		Y	Y					Stack 4 Rack 8 (6 vials)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	g			
HCC1419	LumA	HER2	HER2	Her2	iC7 [Lumninal A, lacks 1q alteration/16p gain/16q loss/ 8q amplification]	Possible ER+	primary		Y	Y			Y (Tina)	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221201_A00827_0713_BHLJV3DRX2_Lupien_Lucie_Tina				Y								o		growing	
HCC1428	LumB	LumB	LumB	Her2	iC1 [ER-positive, 17q23/20q cis-acting luminal B]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0693_AHLJNJDRX2_Lupien_Lucie_Tina				Y						Stack 3 Rack 9 (2 vials)		g		*Jennifer is growing	
HCC1500	LumB	LumB	LumB	LumB	iC6 [ER-positive, 8p12 cis-acting luminal subgroup]	Possible ER+	primary			Y								Y								g			
HCC1569	Basal	Basal	HER2	Basal	iC9 [ER-positive, 8q cis-acting/20q-amplified mixed subgroup]	BL1	primary		Y	Y								Y								y			
HCC1599	Basal	Basal	LumB	Basal	iC9 [ER-positive, 8q cis-acting/20q-amplified mixed subgroup]	BL1	primary			Y						*Purchased from ATCC		Y						Stack 4 Rack 8 (4vials)	***  suspension cells (difficult to perform incucyte assays on)	y			
HCC1806	Basal	Basal	LumB	Basal	iC10 [basal-like, cis-acting alterations (5 loss/8q gain/10p gain/12p gain)]	BL2	primary		Y	Y		Y	Y	HCC1806_4_TCCTGAGC_L002_R1.fastq.gz, HCC1806_5_TAAGGCGA_L002_R1.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/220609_A00827_0591_AHY7F3DRXY_Lupien_Giacomo		0.97	Neg	N	Y				Y	Stack 3 Rack 9 (1 vial)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	y	LT	growing Jenn	
HCC1937	Basal	Basal	LumB	Basal	iC9 [ER-positive, 8q cis-acting/20q-amplified mixed subgroup]	BL2	primary		Y	Y		Y	Y	HCC1937_3_S2_L001_R1_001.fastq.gz,  HCC1937_9_S3_L001_R1_001.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina		*Purchased from ATCC		Y	Y					Stack 4 Rack 8 (3vials)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	y	LT	growing Jenn	
HCC1954	Her2	HER2	HER2	Basal	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	BL2	primary		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				Y								g		growing	
HCC202	Her2	HER2	HER2	Her2	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	LAR	primary		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				Y								g			
HCC2185	LumB	Basal	LumB	Her2	iC3 [luminal A]	LAR	metastatic		Y	Y								N						Stack 3 Rack 9 (2 vials)		o			
HCC2218	LumA	LumB	HER2	Her2	iC1 [ER-positive, 17q23/20q cis-acting luminal B]	LAR	primary			Y								Y								o			
HCC2688	Basal	Basal	LumB	Her2	iC3 [luminal A]	LAR	primary			Y								N								y			
HCC3153	Basal	Basal	Basal	Basal	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	UNS	primary		Y	Y		Y	Y	HCC3153_1_GGACTCCT_L003_R1.fastq.gz,  HCC3153_3_CAGAGAGG_L004_R1.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina		*STR data collected but cell type not in reference database	Neg	N					Y	Stack 3 Rack 9 (2 vials)		g			ATAC-processing-stage & "currently-growing-DC-lab" are temporary columns ; HCC1392, MDA751VII,  MDA351, not here
HCC38	Basal	Basal	Basal	Basal	iC10 [basal-like, cis-acting alterations (5 loss/8q gain/10p gain/12p gain)]	UNS	primary		Y	Y		Y		HCC38_3_CTCTCTAC_L003_R1.fastq.gz, HCC38_6_TCCTGAGC_L003_R1.fastq.gz		0.91	Neg	Y	Y				Y	Stack 1 Rack 9 (2 vials)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	g			** CDK4/6i resistant model control lines from Cescon lab
HCC70	Basal	Basal	LumA	Basal	iC8 [Lumninal A, 1q gain/16q loss]	BL2	primary		Y	Y		Y	Y	HCC70_4_S1_L001_R1_001.fastq.gz,  HCC70_7_S5_L002_R1_001.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/220609_A00827_0591_AHY7F3DRXY_Lupien_Giacomo				Y							Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	y	LC	growing Jenn	
HCC712	LumB	LumB	LumB	LumB	iC1 [ER-positive, 17q23/20q cis-acting luminal B]	Possible ER+	primary			Y								N								g			
HCC812	LumA	HER2	HER2	LumB	iC8 [Lumninal A, 1q gain/16q loss]	Possible ER+	No Info			Y								N							No Info	o			
HDQ-P1	Basal	Basal	LumB	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2/IM	primary		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/220928_A00827_0655_BH7HJKDRX2_Lupien_Lucie				Y						Stack 3 Rack 9 (1 vial)		y		growing Jenn	
Hs-578-T	Basal	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	UNS	primary		Y	Y		Y	Y	HS578_3_GCTACG_L004_R1.fastq.gz,  HS578_6_TAAGGC_L003_R1.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina		1	Neg	Y	Y			Y	Y	Stack 3 Rack 9 (1 vial)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	g	LT/LC	growing Jenn	
JIMT-1	Basal	HER2	LumB	Basal	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	BL2	primary		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				Y						Stack 3 Rack 9 (2 vials)		o			
KPL-1	LumB	LumB	LumB	Her2	iC3 [luminal A]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				N							Problematic cell line: Contaminated. Shown to be a MCF-7 derivative (PubMed 20143388).	r	LC	growing	
LY2	LumB	LumB	LumB	LumB	iC1 [ER-positive, 17q23/20q cis-acting luminal B]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				N								g		growing	
MA-CLS-2	Normal	Basal	Basal	Basal	iC9 [ER-positive, 8q cis-acting/20q-amplified mixed subgroup]	BL2/IM	metastatic			Y								N						Stack 3 Rack 9 (2 vials)		o		growing	
MB 157	Basal	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2	metastatic			Y		Y		MB157_11_S7_L002_R1_001.fastq.gz,  MB157_7_S6_L002_R1_001.fastq.gz				N						Stack 4 Rack 8 (4vials)		g			
MCF10A	Normal	Basal	Basal	Basal	iC3 [luminal A]	BL2	normal			Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				N							fibrocystic changes	o			
MCF12A	Normal	Basal	LumA	Basal	iC3 [luminal A]	Possible ER+	normal			Y								N							fibrocystic changes	o			
MCF7	LumB	LumB	LumB	LumB	iC1 [ER-positive, 17q23/20q cis-acting luminal B]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				Y				Y				g	FRESH **	growing	
MDA-MB-134-VI	LumB	LumB	LumB	LumB	iC2 [ER-positive, 11q13/14 cis-acting luminal tumours]	Possible ER+	metastatic		Y	Y			Y	(Fastq file failed qc)  /cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				N								g			
MDA-MB-157	Basal	Basal	Basal	Basal	iC1 [ER-positive, 17q23/20q cis-acting luminal B]	BL2/MSL	metastatic		Y	Y						*Purchased from ATCC		Y	Y				Y		Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	g			
MDA-MB-175-VII	LumB	LumB	LumB	Her2	iC8 [Lumninal A, 1q gain/16q loss]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				Y						Stack 3 Rack 9 (2 vials)		g	LT		
MDA-MB-231	LumB	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2	metastatic		Y	Y		Y	Y	MDA-MB-231_2_AGGCAG_L004_R1.fastq.gz,  MDA-MB-231_4_TAGGCA_L003_R1.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221121_A00469_0384_AHLJLFDRX2_Lupien_Lucie				Y	Y					Kinjal's box S3 R6 (2 vials)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	o			
MDA-MB-330	LumB	HER2	LumB	Her2	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	Possible ER+	metastatic		Y	Y			Y	(Fastq file failed qc) /cluster/projects/lupiengroup/data/ATAC-seq/2022/220609_A00827_0591_AHY7F3DRXY_Lupien_Giacomo				Y						Stack 3 Rack 9 (2 vials)		o			
MDA-MB-361	Her2	HER2	LumB	Her2	iC1 [ER-positive, 17q23/20q cis-acting luminal B]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				Y								y	LT	growing Isabel (both parental and resistant CDK4/6i)	
MDA-MB-415	LumA	LumB	LumB	Her2	iC3 [luminal A]	Possible ER+	metastatic			Y								Y								o			
MDA-MB-436	Basal	Basal	Basal	Basal	iC10 [basal-like, cis-acting alterations (5 loss/8q gain/10p gain/12p gain)]	UNS	metastatic		Y	Y		Y	Y	MDA-MB-436_3_CTCTCT_L002_R1.fastq.gz, MDA-MB-436_5_CTCTCT_L004_R1.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/220609_A00827_0591_AHY7F3DRXY_Lupien_Giacomo		0.94	Neg	Y	Y			Y	Y	Stack 4 Rack 8 (4vials)	Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	g	LT/LC	MDA436: growing Jenn	
MDA-MB-453	Her2	LumB	HER2	Her2	iC8 [Lumninal A, 1q gain/16q loss]	LAR	metastatic			Y			Y	Did not find in sequencing list - Ankita				Y	Y						Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	o			
MDA-MB-468	Basal	Basal	Basal	Basal	iC3 [luminal A]	BL1	metastatic		Y	Y		Y	Y	MDA-MB-468_4_GGACTC_L002_R1.fastq.gz, MDA-MB-468_5_TCCTGA_L002_R1.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina			Neg	Y	Y			Y	Y		Triple-Negative Breast Cancer Panel 3 (ATCC® TCP-1003™)	g	LT		
MFM-223	LumB	LumB	LumB	Her2	iC8 [Lumninal A, 1q gain/16q loss]	LAR	metastatic		Y	Y								Y								g			
MX-1	Basal	Basal	Basal	Basal	iC9 [ER-positive, 8q cis-acting/20q-amplified mixed subgroup]	BL1	primary		Y	Y		Y		MX1_1_S10_L003_R1_001.fastq.gz, MX1_8_S6_L002_R1_001.fastq.gz			Neg	N						Stack 3 Rack 9 (13 vials)		g		growing Jenn	
OCUB-M	Her2	HER2	HER2	Her2	iC9 [ER-positive, 8q cis-acting/20q-amplified mixed subgroup]	LAR	primary		Y	Y			Y (Tina)	Did not find in sequencing list - Ankita			Neg	Y								g		growing	
SK-BR-3	Her2	HER2	HER2	Her2	iC3 [luminal A]	LAR	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				N						Stack 3 Rack 9 (2 vials)	Originate from same individual AU565	g	LT	growing	
SK-BR-5	Her2	LumB	LumB	Her2	iC2 [ER-positive, 11q13/14 cis-acting luminal tumours]	LAR	primary		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/220609_A00827_0591_AHY7F3DRXY_Lupien_Giacomo				N								y	LC		
SK-BR-7	Normal	Basal	Basal	Her2	iC3 [luminal A]	UNS	primary		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221109_A00827_0694_BHLK53DRX2_Lupien_Lucie_Tina				N						Stack 3 Rack 9 (3 vials)		o		growing	
SUM 1315M02	Basal	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	M/MSL	metastatic			Y								N								g			
SUM 149PT	Basal	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2	primary		Y	Y		Y	Y	SUM149PT_1_S9_L003_R1_001.fastq.gz, SUM149PT_9_S3_L001_R1_001.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221104_A00469_0368_BHH7J2DRX2_Lupien_Lucie			Neg	N				Y	Y			g	LC	growing Jenn	
SUM 159PT	Basal	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	UNS	primary		Y	Y		Y	Y	SUM159PT_1_S1_L001_R1_001.fastq.gz,  SUM159PT_7_S2_L001_R1_001.fastq.gz, /cluster/projects/lupiengroup/data/ATAC-seq/2022/221201_A00827_0713_BHLJV3DRX2_Lupien_Lucie				N				Y	Y			g			
SUM 190	LumA	HER2	HER2	Her2	iC7 [Lumninal A, lacks 1q alteration/16p gain/16q loss/ 8q amplification]	LAR	primary			Y								N								o			
SUM 229PE	Basal	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2	metastatic			Y								N								g			
SUM 52PE	Her2	LumB	Basal	Her2	iC2 [ER-positive, 11q13/14 cis-acting luminal tumours]	LAR	metastatic			Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221031_A00827_0686_BHNWGYDRX2_Lupien_220808_Lucie_tina				N								o			
SUM102PT	Normal	Basal	Basal	Her2	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	BL2	primary			Y								N								o			
SUM185PE	Her2	LumB	Basal	Her2	iC7 [Lumninal A, lacks 1q alteration/16p gain/16q loss/ 8q amplification]	LAR	metastatic			Y								N								o			
SUM225CWN	Normal	HER2	HER2	Her2	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	LAR	primary			Y								N								o			
SUM44PE	LumB	LumB	LumB	LumB	iC2 [ER-positive, 11q13/14 cis-acting luminal tumours]	Possible ER+	metastatic			Y								N								g			
SW 527	LumB	Basal	Basal	Basal	iC4 [ER-positive and ER-negative cases and varied intrinsic subtypes, CNA-devoid]	M/MSL	No Info		Y	Y								N	Y						colon or breast? There is a link claim that it is contaminated http://iclac.org/wp-content/uploads/Cross-Contaminations-v7_2.pdf	r			
T47D	LumB	LumB	LumB	Her2	iC1 [ER-positive, 17q23/20q cis-acting luminal B]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/220928_A00827_0655_BH7HJKDRX2_Lupien_Lucie				Y						Stack 4 Rack 8 (3vials)		g	FRESH **	growing	
UACC-3199	Basal	Basal	Basal	Basal	iC1 [ER-positive, 17q23/20q cis-acting luminal B]	BL1	metastatic			Y							Neg	N								g			
UACC-812	LumB	HER2	HER2	LumB	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	Possible ER+	primary		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/221201_A00827_0713_BHLJV3DRX2_Lupien_Lucie_Tina				Y								o			
UACC-893	Her2	HER2	HER2	Her2	iC5 [ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and luminal (ER-positive) cases]	LAR	primary		Y	Y								Y								g			
ZR-75-1	LumB	LumB	LumB	Her2	iC8 [Lumninal A, 1q gain/16q loss]	Possible ER+	metastatic		Y	Y			Y	/cluster/projects/lupiengroup/data/ATAC-seq/2022/220928_A00827_0655_BH7HJKDRX2_Lupien_Lucie				N								g			
ZR-75-30	LumA	HER2	HER2	Her2	iC3 [luminal A]	Possible ER+	metastatic			Y								Y								o			
ZR75B	LumB	LumB	LumB	Her2	iC8 [Lumninal A, 1q gain/16q loss]	Possible ER+	metastatic			Y								N								g			